article thumbnail

Life Science Trends to Look Out for in 2024

XTalks

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. These companies are at various stages of research and clinical trials.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digitalising drug discovery

pharmaphorum

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75
article thumbnail

Biopharma investment drops by nearly 50% in 2022

Drug Discovery World

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff.

RNA 52
article thumbnail

PharmStars digital health accelerator names its second class of 2022

pharmaphorum

The PharmaStars accelerator was set up last year to help bridge the gap between digital health start-ups and potential pharma partners, which can be instrumental in making sure their technologies meet their potential – and help them to navigate the challenges of developing them in the highly regulated healthcare environment.

article thumbnail

Bigfinite Rebrands as Aizon and Expands AI Expertise

XTalks

Aizon hopes that the rebrand will help drive its superior AI and ML-driven analytical platforms to help serve a wide range of industries within the life sciences and food sector. A fresh or renewed start can be effectively facilitated with a corporate name change to reflect certain changes in a company’s values, missions and interests.